Evidence map›Paper›PMID 41230046›Full record

ReviewTherapeutic advances in chronic disease2025

The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review.

Mohammed Jemal, Nuredin Chura Waritu, Temesgen Baylie, Deresse Sinamaw, Enyew Fenta Mengistu, Enatnesh Essa Osman, Gelagey Baye, Bantayehu Addis Tegegne, Gashaw Azanaw Amare, Zigale Hibstu Teffera and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in chronic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohammed JemalDepartment of Biomedical Science, School of Medicine, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.ORCID https://orcid.org/0009-0000-6700-9972
Nuredin Chura WarituDepartment of Biomedical Sciences, School of Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia.
Temesgen BaylieDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Deresse SinamawDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Enyew Fenta MengistuDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Enatnesh Essa OsmanDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Gelagey BayeDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Bantayehu Addis TegegneDepartment of Pharmacy, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID https://orcid.org/0000-0002-6178-8335
Gashaw Azanaw AmareDepartment of Medical Laboratory Sciences, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Zigale Hibstu TefferaDepartment of Medical Laboratory Sciences, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Tabarak MalikDepartment of Biomedical Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Birhanu MaledeDepartment of Medical Laboratory Sciences, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Baye AshenefDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Desalegn AbebawDepartment of Medical Laboratory Sciences, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Adane AdugnaDepartment of Medical Laboratory Sciences, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition marked by insulin resistance, decreased insulin production, and persistent low-grade inflammation. The prevalence of T2DM has increased significantly in recent decades; as a result, it is now regarded as one of the fastest-growing public health concerns worldwide. Long-term micro- and macrovascular problems such as nephropathy, retinopathy, neuropathy, and cardiovascular disease can be caused by poor blood glucose control. Therefore, developing reliable diagnostic indicators for early diagnosis and investigating new treatment targets are critical for addressing the increasing prevalence of T2DM. Several novel diagnostic approaches have been created by targeting endogenous proteins, with fetuin-A being one of the most promising targets. Human fetuin-A, also referred to as alpha-2-Heremans Schmid glycoprotein, is a liver-produced glycoprotein that is abundantly secreted into the bloodstream and seems to be involved in insulin resistance, metabolic syndrome, and inflammation. Clinical studies have shown that circulating fetuin-A levels are closely associated with T2DM and its complications, underscoring its potential as both a biomarker and a therapeutic target. This narrative review provides a detailed overview of the evolving role of fetuin-A in the development of T2DM and its associated complications, as well as its future perspectives.

Indexed as

biomarkerclinical implicationsfetuin-Ahepatokineinsulin resistanceinsulin signalingmetabolic inflammationtype 2 diabetes mellitus

Identifiers

PMID41230046
PMCPMC12602975

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.